The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 30, 2019

Filed:

May. 27, 2014
Applicant:

The Regents of the University of California, Oakland, CA (US);

Inventors:

Yury Miller, La Jolla, CA (US);

Longhou Fang, La Jolla, CA (US);

Assignee:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/17 (2006.01); A61P 29/00 (2006.01); C07K 14/47 (2006.01); C12N 15/113 (2010.01); C07K 16/18 (2006.01); A61P 3/06 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/47 (2013.01); A61K 38/1709 (2013.01); A61K 38/1761 (2013.01); A61P 29/00 (2018.01); C07K 16/18 (2013.01); C12N 15/113 (2013.01); A61K 38/00 (2013.01); A61P 3/06 (2018.01); C07K 14/4702 (2013.01); C07K 2317/76 (2013.01); C12N 2310/11 (2013.01); C12N 2310/111 (2013.01); C12N 2310/14 (2013.01); C12N 2310/3233 (2013.01);
Abstract

The invention provides pharmaceutical compounds and formulations comprising nucleic acids and polypeptides for regulating (including upregulating or inhibiting) the expression of ApoA-1 Binding Protein (APOAIBP, AIBP, or AI-BP) and methods for making and using them. In alternative embodiments, APOAIBP-inhibiting pharmaceutical compositions and formulations of the invention are administered to an individual in need thereof in an amount sufficient to stimulate tissue revascularizaton, e.g., supporting or stimulating revascularization of heart tissue, e.g., after a cardiac ischemia. In alternative embodiments, pharmaceutical compositions and formulations of the invention that comprise APOAIBP nucleic acids and polypeptides or result in an increase in expression or activity of APOAIBP nucleic acids and polypeptides are administered to an individual in need thereof in an amount sufficient to treat, prevent, reverse and/or ameliorate a dyslipidemia, e.g., to treat, prevent, reverse and/or ameliorate conditions responsive to increasing cholesterol efflux from cells, including cardiovascular disease and atherosclerosis.


Find Patent Forward Citations

Loading…